Healthy
Conditions
Brief summary
Study to investigate the bioavailability of BI 1356 with and without co-administration of pioglitazone and the bioavailability of pioglitazone with and without coadministration of BI 1356
Interventions
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy females and males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), clinical laboratory tests * Age ≥18 and Age ≤65 years * BMI ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index) * Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation
Exclusion criteria
* Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance * Any evidence of a clinically relevant concomitant disease * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * Surgery of the gastrointestinal tract (except appendectomy) * Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * History of relevant orthostatic hypotension, fainting spells or blackouts * Chronic or relevant acute infections (e.g. HIV) * History of relevant allergy/hypersensitivity (including allergy to drug or its excipients) * Intake of drugs with a long half-life (\> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial * Use of drugs which might reasonably influence the results of the trial or that prolong the QT/QTc interval based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial * Participation in another trial with an investigational drug within two months prior to administration or during the trial * Smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day) * Inability to refrain from smoking on trial days * Alcohol abuse (more than 60 g/day) * Drug abuse * Blood donation (more than 100 mL within four weeks prior to administration or during the trial) * Excessive physical activities (within one week prior to administration or during the trial) * Any laboratory value outside the reference range that is of clinical relevance * Inability to comply with dietary regimen of trial site * A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \>450 ms) * A history of additional risk factors for Torsade de Pointes (TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome) For male subjects: * Not willing to use adequate contraception (condom use plus another form of contraception e.g. spermicide, oral contraceptive taken by female partner, sterilisation, IUD \[intrauterine device\]) during the whole study period from the time of the first intake of study drug until one month after the last intake For female subjects: * Pregnancy or planning to become pregnant within 2 months of study completion * Positive pregnancy test * Are not willing or are unable to use a reliable method of contraception (such as implants, injectibles and combined oral contraceptives, sterilisation, IUD, double barrier method) for at least 3 months prior to participation in the trial, during and up to 2 months after completion/termination of the trial * Chronic use of oral contraception or hormone replacement containing ethinyl estradiol as the only method of contraception * Lactation period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ) | up to 21 days |
| Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) | up to 21 days |
Secondary
| Measure | Time frame |
|---|---|
| CL/F,ss (apparent clearance of the analyte in the plasma after extravascular administration at steady state) | up to 21 days |
| tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state) | up to 21 days |
| C24,ss (concentration of the analyte in plasma at steady state after administration of the last dose at the end of the dosing interval) | up to 21 days |
| λz,ss (terminal rate constant in plasma at steady state) | up to 21 days |
| t1/2,ss (terminal half-life of the analyte in plasma at steady state) | up to 21 days |
| MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration) | up to 21 days |
| Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration) | up to 21 days |
| Changes in physical examination (including body weight) | up to 27 days after last administration of study medication |
| Changes in Vital signs (Blood pressure (BP), Pulse Rate (PR) | up to 27 days after last administration of study medication |
| Changes in 12-lead ECG (electrocardiogram) | up to 27 days after last administration of study medication |
| Changes in clinical laboratory values | up to 27 days after last administration of study medication |
| Number of patients with adverse events | up to 27 days after last administration of study medication |
| Assessment of tolerability by investigator on a 4-point scale | up to 27 days after last administration of study medication |
Outcome results
None listed